Adverse events66

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

61 to 66 of 66

Type	Event	Organ system	Group	Affected	At risk
serious	Generalised tonic-clonic seizure	Nervous system disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
serious	Generalised tonic-clonic seizure	Nervous system disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	1	34
serious	Guillain-Barre syndrome	Nervous system disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
serious	Guillain-Barre syndrome	Nervous system disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	1	34
serious	Deep vein thrombosis	Vascular disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	1	57
serious	Deep vein thrombosis	Vascular disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	0	34

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03648541/events?page=4